For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
September 17, 2001
- METI Recommends Modernization of Trade Practices in Japan
September 17, 2001
- Kureha, Sankyo to Codevelop Kremezin in US
September 17, 2001
- BULLETIN
September 17, 2001
- Wholesalers Should Charge for Immediate PMS Services: Mr Masuda of Kuraya Sanseido
September 17, 2001
- OTC NEWS IN BRIEF
September 17, 2001
- BUSINESS NEWS IN BRIEF
September 17, 2001
- Cholesterol Levels in Postmenopausal Women to Be Surveyed
September 17, 2001
- MEDICAL DEVICE NEWS IN BRIEF
September 10, 2001
- REGULATORY NEWS IN BRIEF -2-
September 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
September 10, 2001
- REGULATORY NEWS IN BRIEF -1-
September 10, 2001
- Sanyo, NEC Tie Up Regarding Medical Information Systems
September 10, 2001
- Mr Hashimoto Stresses Establishing Durable Social Security System
September 10, 2001
- WORLD NEWS IN BRIEF
September 10, 2001
- Healthcare Industry Can Be Driving Power of Economy: METI Minister
September 10, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 10, 2001
- METI Demands \1,015.1 Bil., Up 9.09%
September 10, 2001
- Clinical Study to Collect Data on Ethnic Differences Completed
September 10, 2001
- Monkasho Demands \91,023 Mil. to Promote Life Science
September 10, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…